A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs HMPL-760 (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors HUTCHMED
- 19 Nov 2024 Status changed from not yet recruiting to recruiting.
- 30 Sep 2024 New trial record